Global Myasthenia Gravis Drugs Market – Analysis, Technologies & Forecasts to 2021 – Limited Availability of Approved Drugs Is a Key Market Challenge – Research and Markets

DUBLIN–(BUSINESS WIRE)– Research and Markets has announced the addition of the « Global
Myasthenia Gravis Drugs Market 2017-2021″ report to their
offering.

The global myasthenia gravis drugs market to grow at a CAGR of 13.16%
during the period 2017-2021.

Global Myasthenia Gravis Drugs Market 2017-2021, has been prepared based
on an in-depth market analysis with inputs from industry experts. The
report covers the market landscape and its growth prospects over the
coming years. The report also includes a discussion of the key vendors
operating in this market.

According to the report, myasthenia gravis is the common disorder of
neuromuscular transmission. The presence of large patient pool with
myasthenia gravis is expected to fuel the market growth. The data
estimates suggest that out of the existing patient pool in the US,
approximately 15%-20% of people will experience a myasthenic crisis (a
complication of myasthenia gravis resulting in severe muscle weakness,
leading to respiratory failure). Three-fourths of these cases experience
their first crisis within two years of diagnosis.

Key vendors

• Flamel Technologies
• F. Hoffmann-La Roche
• Grifols
• Pfizer
• Shire
• Valeant Pharmaceuticals

Other prominent vendors

• Alexion Pharmaceuticals
• Catalyst Pharmaceuticals
• CSL
• Curavac
• Cytokinetics
• Galencia
• GlaxoSmithKline
• Lupin Pharmaceuticals
• Mitsubishi Tanabe Pharma
• Novartis

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Pipeline analysis

Part 06: Market landscape

Part 07: Market segmentation by therapy area

Part 08: Geographical segmentation

Part 09: Market drivers

Part 10: Impact of drivers

Part 11: Market challenges

Part 12: Impact of drivers and challenges

Part 13: Market trends

Part 14: Vendor landscape

Part 15: Key vendor analysis

Part 16: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/mtcckk/global_myasthenia.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170125005689/en/